Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions

New England Journal of Medicine

Volumn 337, Issue 26, 1997, Pages 1861-1869

  Slichter, Sherrill J ^a  

^a PUGET SOUND BLOOD CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOIMMUNIZATION; ARTICLE; BLEEDING TENDENCY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOCYTOPHERESIS; TREATMENT OUTCOME; ULTRAVIOLET B RADIATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, HUMAN PLATELET; BLOOD COMPONENT REMOVAL; BLOOD GROUP INCOMPATIBILITY; BLOOD PLATELETS; DOUBLE-BLIND METHOD; FEMALE; FILTRATION; HUMANS; ISOANTIBODIES; LEUKEMIA, MYELOID; LEUKOCYTES; LYMPHOCYTES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PLATELET TRANSFUSION; THROMBOCYTOPENIA; ULTRAVIOLET RAYS;

EID: 2642611953     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199712253372601     Document Type: Article

References (52)

1. Duquesnoy RJ, Filip DI, Rodey GE, Rimm AA, Aster RH. Successful transfusion of platelets "mismatched" for HLA antigens to alloimmunized thrombocytopenic patients. Am J Hematol 1977;2:219-26.
2. Schiffer CA, Dutcher JP, Aisner J, Hogge D, Wiernik PH, Reilly JP. A randomized trial of leukocyte-depleted platelet transfusion to modify alloimmunization in patients with leukemia. Blood 1983;62:815-20.
3. Murphy MF, Metcalfe P, Thomas H, et al. Use of leucocyte-poor blood components and HLA-matched-platelet donors to prevent HLA alloimmunization. Br J Haematol 1986;62:529-34.
4. Sniecinski I, O'Donnell MR, Nowicki B, Hill LR. Prevention of refractoriness and HLA-alloimmunization using filtered blood products. Blood 1988;71:1402-7.
5. Andreu G, Dewailly J, Leberre C, et al. Prevention of HLA immunization with leukocyte-poor packed red cells and platelet concentrates obtained by filtration. Blood 1988;72:964-9.
6. Oksanen K, Kekomaki R, Ruutu T, Koskimies S, Myllyla G. Prevention of alloimmunization in patients with acute leukemia by use of white cell-reduced blood components - a randomized trial. Transfusion 1991;31: 588-94.
7. van Marwijk Kooy M, van Prooijen HC, Moes M, Bosma-Stants I, Akkerman JWN. The use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: a prospective, randomized trial. Blood 1991;77:201-5.
8. Williamson LM, Wimperis JZ, Williamson P. Bedside filtration of blood products in the prevention of HLA alloimmunization - a prospective randomized study: Alloimmunization Study Group. Blood 1994;83:3028-35.
9. Claas FHJ, Smeenk RJT, Schmidt R, van Steenbrugge GJ, Eernisse JG. Alloimmunization against the MHC antigens after platelet transfusions is due to contaminating leukocytes in the platelet suspension. Exp Hematol 1981;9:84-9.
10. Kripke ML. Immunologic unresponsiveness induced by ultraviolet radiation. Immunol Rev 1984;80:87-102.
11. Lindahl-Kiessling K, Safwenberg J. Inability of UV-irradiated lymphocytes to stimulate allogeneic cells in mixed lymphocyte culture. Int Arch Allergy Appl Immunol 1971;41:670-8.
12. Gmur J, von Felten A, Osterwalder B, et al. Delayed alloimmunization using random single donor platelet transfusions: a prospective study in thrombocytopenic patients with acute leukemia. Blood 1983;62:473-9.
13. Sintnicolaas K, Vriesendorp HM, Sizoo W, et al. Delayed alloimmunisation by random single donor platelet transfusions: a randomised study to compare single donor and multiple donor platelet transfusions in cancer patients with severe thrombocytopenia. Lancet 1981;1:750-4.
14. Murphy S, Heaton WA, Rebulla P. Platelet production in the old world - and the new. Transfusion 1996;36:751-4.
15. Kao KJ, Scornik JC. Accurate quantitation of the low number of white cells in white cell-depleted blood components. Transfusion 1989;29:774-7.
16. Schiffer CA, Lee EJ, Ness PM, Reilly J. Clinical evaluation of platelet concentrates stored for one to five days. Blood 1986;67:1591-4.
17. Fuller TC, Phelan DL, Gebel HM, Rodey GE. Antigenic specificity of antibody reactive in the antiglobulin-augmented lymphocytotoxicity test. Transplantation 1982;34:24-9.
18. Terasaki PI, Bernoco D, Park MS, Ozturk G, Iwaki Y. Microdroplet testing for HLA-A, -B, -C, and -D antigens: the Phillip Levine Award Lecture. Am J Clin Pathol 1978;69:103-20.
19. Schiffer CA, Young V. Detection of platelet antibodies using a microenzyme-linked immunosorbent assay (ELISA). Blood 1983;61:311-7.
20. Howe SE, Lynch DM, Lynch JM. An enzyme-linked immunosorbent assay for the quantification of serum platelet-bindable IgG. Transfusion 1984;24:348-52.
21. Collins J, Aster RH. Use of immobilized platelet membrane glycoproteins for the detection of platelet-specific alloantibodies in solid-phase ELISA. Vox Sang 1987;53:157-61.
22. Visentin GP, Wolfmeyer K, Newman PJ, Aster RH. Detection of drug-dependent, platelet-reactive antibodies by antigen-capture ELISA and flow cytometry. Transfusion 1990;30:694-700.
23. Curtis BR, McFarland JG, Wu GG, Visentin GP, Aster RH. Antibodies in sulfonamide-induced immune thrombocytopenia recognize calcium-dependent epitopes on the glycoprotein IIb/IIIa complex. Blood 1994; 84:176-83.
24. Furihata K, Nugent DJ, Bissonette A, Aster RH, Kunicki TJ. On the association of the platelet-specific alloantigen, Pena, with glycoprotein IIIa: evidence for heterogeneity of glycoprotein IIIa. J Clin Invest 1987;80: 1624-30.
25. Kekomaki R, Dawson B, McFarland J, Kunicki TJ. Localization of human platelet autoantigens to the cysteine-rich region of glycoprotein IIIa. J Clin Invest 1991;88:847-54.
26. Rubinstein LV, Gail MH, Santner TJ. Planning the duration of a comparative clinical trial with loss to follow-up and a period of continued observation. J Chronic Dis 1981;34:469-79.
27. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979;35:549-56.
28. Kao KJ, Mickel M, Braine HG, et al. White cell reduction in platelet concentrates and packed red cells by filtration: a multicenter clinical trial. Transfusion 1995;35:13-9.
29. Lutz P, Dzik WH. Large-volume hemocytometer chamber for accurate counting of white cells (WBCs) in WBC-reduced platelets: validation and application for quality control of WBC-reduced platelets prepared by apheresis and filtration. Transfusion 1993;33:409-12.
30. Kickler TS, Kennedy SD, Braine HG. Alloimmunization to platelet-specific antigens on glycoproteins IIb-IIIa and Ib/IX in multiply transfused thrombocytopenic patients. Transfusion 1990;30:622-5.
31. Brand A, van Leeuwen A, Eernisse JG, van Rood JJ. Platelet transfusion therapy: optimal donor selection with a combination of lymphocytotoxicity and platelet fluorescence tests. Blood 1978;51:781-8.
32. Kickler TS, Braine HG, Ness PM. The predictive value of platelet crossmatching. Transfusion 1985;25:385-9.
33. Brand A, Claas FHJ, Voogt PJ, Wasser MNJM, Eernisse JG. Alloimmunization after leukocyte-depleted multiple random donor platelet transfusions. Vox Sang 1988;54:160-6.
34. Sintnicolaas K, van Marwijk Kooij M, van Prooijen HC, et al. Leukocyte depletion of random single-donor platelet transfusions does not prevent secondary human leukocyte antigen-alloimmunization and refractoriness: a randomized prospective study. Blood 1995;85:824-8.
35. Andreu G, Dewailly J. Prevention of HLA alloimmunization by using leukocyte-depleted components. Curr Stud Hematol Blood Transfus 1994; 60:29-40.
36. Blundell EL, Pamphilon DH, Fraser ID, et al. A prospective, randomized study of the use of platelet concentrates irradiated with ultraviolet-B light in patients with hematologic malignancy. Transfusion 1996;36:296-302.
37. Andreu G, Boccaccio C, Lecrubier C, et al. Ultraviolet irradiation of platelet concentrates: feasibility in transfusion practice. Transfusion 1990; 30:401-6.
38. Grijzenhout MA, Aarts-Riemens MI, de Gruijl FR, van Weelden H, van Prooijen HC. UVB irradiation of human platelet concentrates does not prevent HLA alloimmunization in recipients. Blood 1994;84:3524-31.
39. Pamphilon DH, Potter M, Cutts M, et al. Platelet concentrates irradiated with ultraviolet light retain satisfactory in vitro storage characteristics and in vivo survival. Br J Haematol 1990;75:240-4.
40. Sherman L, Menitove J, Kagen LR, et al. Ultraviolet-B irradiation of platelets: a preliminary trial of efficacy. Transfusion 1992;32:402-7.
41. Holohan TV, Terasaki PI, Deisseroth AB. Suppression of transfusion-related alloimmunization in intensively treated cancer patients. Blood 1981;58:122-8.
42. Lee EJ, Schiffer CA. Serial measurement of lymphocytotoxic antibody and response to nonmatched platelet transfusions in alloimmunized patients. Blood 1987;70:1727-9.
43. Norol F, Kuentz M, Cordonnier C, et al. Influence of clinical status on the efficacy of stored platelet transfusion. Br J Haematol 1994;86:125-9.
44. Hogge DE, Dutcher JP, Aisner J, Schiffer CA. Lymphocytotoxic antibody is a predictor of response to random donor platelet transfusion. Am J Hematol 1983;14:363-9.
45. Friedberg RC, Donnelly SF, Boyd JC, Gray LS, Mintz PD. Clinical and blood bank factors in the management of platelet refractoriness and alloimmunization. Blood 1993;81:3428-34.
46. Bishop JF, McGrath K, Wolf MM, et al. Clinical factors influencing the efficacy of pooled platelet transfusions. Blood 1988;71:383-7.
47. Bowden RA, Slichter SJ, Sayers M, et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 1995;86:3598-603.
48. Corash L, Cook D, Reames A, Arnstein P. Photochemical decontamination of platelet concentrates prevents transfusion induced cytomegalovirus infection. Blood 1994;84:Suppl 1:530a. abstract.
49. Grass J, Hei D, Wiesehahn GP, Corash L, Lin L. Inactivation of T-cells with psoralens and UVA in human platelet concentrates. Blood 1995;86: Suppl 1:542a. abstract.
50. Blajchman MA. The effect of leukodepletion on allogeneic donor platelet survival and refractoriness in an animal model. Semin Hematol 1991;28:Suppl 5:14-7.
51. Grijzenhout MA, Aarts-Riemens MI, Claas FHJ, van Prooijen HC. Prevention of MHC-alloimmunization by UV-B irradiation in a murine model: effects of UV dose and number of transfused cells. Br J Haematol 1994;87:598-604.
52. Fish D, Abrams K, Slichter SJ. Prevention of alloimmune platelet (PLT) refractoriness in a dog PLT transfusion (TX) model requires both leukocyte (WBC) reduction plus either red blood cell (RBC) reduction or ultraviolet-B (UV-B) irradiation. Blood 1995;86:Suppl 1:541a. abstract.